Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 59-year-old woman with advanced gastric cancer was treated with continuous 5-fluorouracil infusion for thirty-five days. Endoscopy of the upper gastrointestinal tract was performed due to continuing nausea seven days after the cessation of 5-fluorouracil infusion and revealed multiple erosions in the antrum which were absent before chemotherapy. Continuous 5-fluorouracil infusion was probably the cause of acute gastric mucosal lesions and should be included in the differential diagnosis of dyspepsia in 5-FU-treated patients.
 ...
PMID:Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions. 840 11

A 45-year-old woman who suffered from left breast cancer, 8 cm in diameter, with skin invasion and axillary lymph node involvement but no distant metastasis, underwent neoadjuvant chemotherapy. FEC100 consisting of 5-FU (500 mg/m(2)), epirubicin (100 mg/m(2)) and cyclophosphamide (500 mg/m(2)), were given intravenously for tumor reduction in connection with breast conserving surgery. Although antiemetic agents such as granisetron hydrochloride,metoclopramide and dexamethasone failed to prevent frequent emesis and loss of appetite in the first course, TSUMURA Rikkunshi-to Extract Granules (Rikkunshi-to) in addition to those antiemetic agents from the second course remarkably well controlled nausea and vomiting. Consequently, 6 courses of neoadjuvant chemotherapy were carried out successfully and brought about complete tumor remission. Rikkunshi-to was first medicated for non-ulcer dyspepsia, but now we suggest that it is possibly a good new antiemetic agent.
 ...
PMID:[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient]. 1691 33